Kyle Plusch, | |
2 Medical Park Rd, Columbia, SC 29203-6808 | |
(803) 434-6879 | |
Not Available |
Full Name | Kyle Plusch |
---|---|
Gender | Male |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 2 Medical Park Rd, Columbia, South Carolina |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1205531621 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207X00000X | Orthopaedic Surgery | LL90030 (South Carolina) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Kyle Plusch, 2 Medical Park Rd, Columbia, SC 29203-6808 Ph: () - | Kyle Plusch, 2 Medical Park Rd, Columbia, SC 29203-6808 Ph: (803) 434-6879 |
News Archive
Human Genome Sciences, Inc.announced today that it has received a clinical development milestone payment from its partner, GlaxoSmithKline, related to the initiation of Phase 1 clinical trials of 677116 for the treatment of cardiovascular disease. 677116 is a small-molecule inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme associated with the formation of atherosclerotic plaques.
For chronic pain sufferers, a day can feel like a year and a year can feel like an eternity. With very few truly new therapies approved by the U.S. Food and Drug Administration for this condition since 2005, the outlook is far from bright.
Diabetes describes a disease where the body is not receiving a sufficient supply of insulin. It commonly inflicts the pancreas, the organ responsible for insulin production. More specifically, it inflicts the cells that produce insulin, which are found in the endocrine tissue of the pancreas.
Genzyme, a Sanofi company, announced it has received a Refuse to File letter from the U.S. Food and Drug Administration (FDA) in response to the supplemental Biologics License Application (sBLA) for the approval of LEMTRADA (alemtuzumab) as a treatment for relapsing multiple sclerosis.
› Verified 8 days ago